This recruiting study focuses on depression and currently lists sites or participation links in United States.
This study exists to compare options and see whether the medication SP-624 offers something meaningfully different. For people living with Depression, that matters because care needs to work in daily life, not just in theory. The findings could guide better understanding and future care, and taking part helps build that evidence for others.
The official record suggests in-person participation through a lab, with sites including IMA Clinical Research in Phoenix, Noble Clinical Research in Tucson, and SanRo Clinical Research Group in Bryant. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and meeting the main study requirements, while common reasons not to take part include pregnancy or breastfeeding and other factors that could make participation unsuitable. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordTaking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United States.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com